바이오의약품 수탁 제조 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global biopharmaceuticals contract manufacturing market size is expected to reach USD 121.32 Billion in 2034 from USD 46.93 Billion in 2025, growing at a CAGR of 11.13% during 2026-2034.The global biopharmaceuticals contract manufacturing market is witnessing rapid expansion due to the increasing demand for biologics, biosimilars, and complex therapeutic products. Pharmaceutical companies are increasingly outsourcing manufacturing processes to contract manufacturing organizations (CMOs) to reduce costs and streamline operations. This trend has significantly contributed to the growth of the market across various regions.

Major growth drivers include the rising prevalence of chronic diseases, increased investment in research and development, and the complexity of biologic drug production. Contract manufacturers provide specialized expertise, advanced technologies, and regulatory support, making them valuable partners. Additionally, the need for flexible and scalable production capabilities is further boosting market demand.

Looking ahead, the market is poised for substantial growth driven by innovations in bioprocessing and the emergence of personalized medicine. The development of gene therapies and advanced biologics will create new opportunities for CMOs. As pharmaceutical companies continue to focus on innovation and efficiency, contract manufacturing will remain a key strategic component in the industry.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Source

• Mammalian
• Non-mammalian

By Service

• Process Development
• Fill & Finish Operations
• Analytical & QC studies
• Packaging & Labelling
• Others

By Drug Type

• Biologics
• Biosimilars

By Type

• Drug Substance
• Finished Drug Product

By Scale of Operation

• Clinical
• Commercial

By Therapeutic Area

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Neurology
• Others

COMPANIES PROFILED

• Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific, Catalent, Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim BioXcellence, AGC Biologics, Rentschler Biopharma, Emergent BioSolutions, KBI Biopharma, Just-Evotec Biologics, Bio Base Europe Pilot Plant, Cytovance Biologics, Piramal Pharma Solutions, AbbVie Contract Manufacturing, Siegfried, WuXi Vaccines, Curia, Avid Bioservices

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SERVICE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Service
• 5.2. Process Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Fill & Finish Operations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Analytical & QC studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Packaging & Labelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Type
• 6.2. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biosimilars Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Type
• 7.2. Drug Substance Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Finished Drug Product Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SCALE OF OPERATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Scale Of Operation
• 8.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Therapeutic Area
• 9.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.6. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.7. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Source
  • 10.2.2 By Service
  • 10.2.3 By Drug Type
  • 10.2.4 By Type
  • 10.2.5 By Scale Of Operation
  • 10.2.6 By Therapeutic Area
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Source
  • 10.3.2 By Service
  • 10.3.3 By Drug Type
  • 10.3.4 By Type
  • 10.3.5 By Scale Of Operation
  • 10.3.6 By Therapeutic Area
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Spain
  • 10.3.12 Russia
  • 10.3.13 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Source
  • 10.4.2 By Service
  • 10.4.3 By Drug Type
  • 10.4.4 By Type
  • 10.4.5 By Scale Of Operation
  • 10.4.6 By Therapeutic Area
  • 10.4.7 China
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 India
  • 10.4.11 Australia
  • 10.4.12 South East Asia
  • 10.4.13 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Source
  • 10.5.2 By Service
  • 10.5.3 By Drug Type
  • 10.5.4 By Type
  • 10.5.5 By Scale Of Operation
  • 10.5.6 By Therapeutic Area
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Source
  • 10.6.2 By Service
  • 10.6.3 By Drug Type
  • 10.6.4 By Type
  • 10.6.5 By Scale Of Operation
  • 10.6.6 By Therapeutic Area
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Lonza
  • 12.2.2 Samsung Biologics
  • 12.2.3 WuXi Biologics
  • 12.2.4 Thermo Fisher Scientific
  • 12.2.5 Catalent
  • 12.2.6 Fujifilm Diosynth Biotechnologies
  • 12.2.7 Boehringer Ingelheim BioXcellence
  • 12.2.8 AGC Biologics
  • 12.2.9 Rentschler Biopharma
  • 12.2.10 Emergent BioSolutions
  • 12.2.11 KBI Biopharma
  • 12.2.12 Just-Evotec Biologics
  • 12.2.13 Bio Base Europe Pilot Plant
  • 12.2.14 Cytovance Biologics
  • 12.2.15 Piramal Pharma Solutions
  • 12.2.16 AbbVie Contract Manufacturing
  • 12.2.17 Siegfried
  • 12.2.18 WuXi Vaccines
  • 12.2.19 Curia
  • 12.2.20 Avid Bioservices